---
title: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
nct_id: NCT06934408
overall_status: RECRUITING
phase: PHASE1
sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
study_type: INTERVENTIONAL
primary_condition: Obesity
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06934408.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06934408"
ct_last_update_post_date: 2025-11-17
last_seen_at: "2026-05-12T06:01:06.918Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

**Official Title:** A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Injections of HRS-5817 Injection in Healthy Adult Volunteers With or Without Obesity

**NCT ID:** [NCT06934408](https://clinicaltrials.gov/study/NCT06934408)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 92
- **Lead Sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Conditions:** Obesity, Overweight
- **Start Date:** 2025-05-08
- **Completion Date:** 2027-04
- **CT.gov Last Update:** 2025-11-17

## Brief Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single and multiple doses in adults who are affected by obesity.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Voluntarily sign the informed consent form prior to any study-related activities, understand the procedures and methods of the study, and agree to complete this study in strict accordance with the clinical study protocol.
2. Males or females aged 18-55 years old (inclusive).
3. Subjects who are generally healthy as judged by the investigator based on medical history, vital signs, physical examination, laboratory tests and electrocardiogram (ECG) results.
4. Body weight change (difference between the maximum body weight and the minimum body weight within 3 months) of no more than 5 kg within the past 3 months.
5. Female subjects of childbearing potential must agree to take highly effective contraceptive measures and avoid egg donation from the signing of the informed consent form to 6 months after the last dose, and must have a negative blood pregnancy test result before administration and not be breastfeeding. Male subjects whose partners are women of childbearing potential must agree to take highly effective contraceptive measures and avoid sperm donation from the signing of the informed consent form to 6 months after the last dose.

Exclusion Criteria:

1. Known or suspected allergy to any ingredient in the investigational medicinal products or related products; or history of multiple and/or severe allergies to drugs or food, or history of severe anaphylaxis.
2. History of or suffering from major diseases of cardiovascular, endocrine (except primary obesity), mental, neurological, digestive, respiratory, blood, immune or genitourinary systems, which are not suitable for participation in this study as judged by the investigator.
3. Subjects who have had severe trauma or undergone major surgical procedures within 6 months before screening, or who plan to undergo surgery during the study.
4. Subjects who have participated in and used any other clinical trial drugs or medical device treatments within 3 months prior to screening or plan to do so during the study period, or within 5 half-lives of the investigational drug before screening (whichever is longer).
5. Significant changes in diet and exercise habits within 1 month before screening, or failure to maintain a basically stable lifestyle such as diet and exercise during the study.
6. Known or suspected history of drug abuse or substance abuse, or positive urine drug screening during the screening period.
7. Other situations that may interfere with the evaluation of the study results or are not suitable for participating in this study as judged by the investigator.
```

## Arms

- **HRS-5817 Injection Group** (EXPERIMENTAL)
- **HRS-5817 Injection Placebo Group** (PLACEBO_COMPARATOR)

## Interventions

- **HRS-5817 Injection** (DRUG) — HRS-5817 injection administered subcutaneously (SC).
- **HRS-5817 Injection Placebo** (DRUG) — HRS-5817 injection placebo administered subcutaneously (SC).

## Primary Outcomes

- **Adverse events (AEs)** _(time frame: Baseline up to Day 253.)_

## Secondary Outcomes

- **Area Under the curve from time 0 to time t (AUC0-t)** _(time frame: 0 to anticipated 253 days.)_
- **Area Under the curve from time 0 to infinity (AUC0-∞)** _(time frame: 0 to anticipated 253 days.)_
- **Maximum concentration (Cmax)** _(time frame: 0 to anticipated 253 days.)_
- **Time to reach maximum concentration (Tmax)** _(time frame: 0 to anticipated 253 days.)_
- **Half-life (t1/2)** _(time frame: 0 to anticipated 253 days.)_
- **Apparent clearance (CL/F)** _(time frame: 0 to anticipated 253 days.)_
- **Proportion of anti-drug antibodies (ADA) positive subjects** _(time frame: 0 to anticipated 253 days.)_

## Locations (1)

- The Second Hospital of Anhui Medical Uniersity, Hefei, Anhui, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the second hospital of anhui medical uniersity|hefei|anhui|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06934408.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06934408*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*